What Makes a Peptide Generic: FDA's July 2026 Impurity Thresholds, the First Generic Semaglutide Approvals, and What a Research CoA Cannot Show

Our 148,085-post Reddit corpus contains the word "legit" in 1,996 posts and "bioequivalence" in zero posts. A whole-corpus text check on 29 August 2026 located zero posts naming the regulatory standard that the word "generic" actually means in the United States, in a community that argues about which peptide vendor to trust: an Abbreviated New Drug Application (ANDA) under section 505(j) of the FD&C Act, showing the same active ingredient as a reference product and an impurity profile characterized against numeric thresholds and against that product, with immunogenicity risk assessed for every new impurity. The rules changed on 28 July 2026, when FDA withdrew its 2021 synthetic-peptide guidance and published 17 revised draft guidances setting new thresholds. This article lays out what the standard says, in its own words, where the US record stands at four peptides with five first-generic approval entries, where semaglutide stands, where the world outside the US has gone, and what a research-use certificate of analysis does and does not show against any of it.

Retatrutidemetabolic

First-ever triple-action weight management peptide targeting three receptors at once: GLP-1, GIP, and glucagon. Shown exceptional results in Phase 2 trials - up to 24% weight reduction. The most advanced metabolic peptide available.

Tirzepatidemetabolic

A first-in-class dual GIP and GLP-1 receptor agonist, and one of the most extensively studied compounds in modern metabolic and weight-regulation research. Supplied as a lyophilised research peptide with a per-batch certificate of analysis, for laboratory and in-vitro use only.

Metabolic Researchmetabolic

GIP/GLP-1/Glucagon agonists and metabolic pathways

What "generic" means for a peptide in the US

FDA's regulatory boundary for a peptide starts with size, not manufacturing origin, part of a wider set of 2026 changes to US peptide regulation. The agency's May 2021 guidance (withdrawn 28 July 2026) states, verbatim: "FDA considers any alpha amino acid polymer composed of 40 or fewer amino acids to be a peptide, not a protein. Glucagon, liraglutide, nesiritide, teriparatide, and teduglutide are peptides. A peptide is regulated as a drug under the FD&C Act unless the peptide otherwise meets the statutory definition of a "biological product" (e.g., a peptide vaccine) and is therefore regulated under the Public Health Service Act." (source 1) The 40-amino-acid line traces to FDA's final rule "Definition of the Term 'Biological Product'" (85 FR 10057, February 21, 2020); the guidance does not say what happens to a peptide of more than 40 amino acids.

The guidance's scope named five products directly: "Specifically, this guidance provides recommendations for evaluating whether an ANDA submission is appropriate for a synthetic peptide that references any of the following five previously approved peptide drug products of rDNA origin: glucagon, liraglutide, nesiritide, teriparatide, and teduglutide." A footnote drew the boundary the other way too: "This guidance does not address ANDAs for peptides of rDNA origin." FDA did not expect at that time that an ANDA could include sufficient evidence, for example clinical investigations to assess potential immunogenicity, for approval of a proposed peptide of rDNA origin. Its own reason for opening the pathway was analytical: given advances in synthesis and characterization technology, FDA judged an ANDA applicant could demonstrate "...the active ingredient in a proposed generic synthetic peptide is the same as the active ingredient in the RLD that is of rDNA origin..." A whole-document text check on 29 August 2026 located the phrase "highly purified synthetic peptide" three times in the guidance, all of them in the title, and zero times in its body text.

The guidance traces to a 2017 draft (82 FR 46075), finalized May 20, 2021 (86 FR 27446, docket FDA-2017-D-5767) by the Office of Generic Drugs in CDER (source 2). On sameness of active ingredient: "The sameness of active ingredient in a proposed generic synthetic peptide can be established through physicochemical characterization, and biological evaluation such as comparative clinical pharmacokinetic (PK) and/or pharmacodynamic (PD) studies." On analytics: "For such applications, FDA recommends that applicants apply sensitive and high resolution analytical procedures (e.g., UHPLC-HRMS) to detect and characterize peptide-related impurities in a proposed generic synthetic peptide in comparison to the RLD." (source 1)

The impurity arithmetic: 2021, July 2026, and the EU

The withdrawn 2021 guidance recommended, verbatim: "In general, for the peptides covered by this guidance, applicants should identify each peptide-related impurity that is 0.10 percent of the drug substance or greater." It treated an ANDA as generally appropriate if the applicant could, among other things, "...2) show that the proposed generic synthetic peptide does not contain any new specified peptide-related impurity that is more than 0.5 percent of the drug substance...", with each new specified peptide-related impurity characterized and justified. Its reason: "A new peptide-related impurity level higher than 0.5 percent of the drug substance could raise concerns about the potential risk of immunogenicity..." That figure was not presented as a fixed bar. FDA wrote that it "...is consistent with the small amount of unspecified peptide-related impurities observed in finished peptide drug products due to batch-to-batch variability, which occurs regardless of whether the peptide is produced by a recombinant or synthetic process. This flexibility is, however, subject to subsequent scientific review upon the submission of an ANDA and FDA may ask the ANDA applicant to further reduce the level of a specified peptide-related impurity depending on the risks associated with a particular impurity as well as with the proposed drug product." (source 1) The full comparison is in the table below.

That guidance is gone. On 28 July 2026, FDA stated: "Today, the Food and Drug Administration published 17 revised draft product-specific guidances (PSGs) for peptide products, marking a significant advancement in the agency's scientific and regulatory approach to generic peptide drug assessment." The 17 draft documents cover nine active ingredients across five areas, impurity thresholds among them (source 3). FDA withdrew the 2021 guidance "...as it no longer reflects FDA's current scientific thinking." Its stated plan: "...FDA plans to revise the guidance this year." The Federal Register notice, 91 FR 47834, docket FDA-2007-D-0369, comments due 28 September 2026, says "...revise and reissue the guidance this year..." (source 4). As of 29 August 2026, no revised or reissued version of the withdrawn guidance was located in the Federal Register API, and the withdrawn guidance's live PDF URL returns HTTP 404 (source 1).

The 17 drafts are each marked Draft, Not for Implementation, with byte-identical threshold wording in the liraglutide, teriparatide and glucagon drafts and the same a-to-d threshold wording in the semaglutide draft for NDA 215256, all most recently revised in July 2026 (source 5) (source 6) (source 7) (source 8) (source 9). Quoted in relevant part from the liraglutide draft (NDA 022341): "...Identify all active ingredient-related impurities present in the proposed generic peptide drug product at a level above 0.5% of the drug substance... the level of the active ingredient-related impurity... should not be greater than that found in the RLD or 1.0% of the drug substance, whichever is greater..." with new impurities to be brought "below 1.0% of the drug substance" and total impurities held to the RLD's own total (source 10). A clause in the drafts addresses impurities outside those levels: "The presence of a new or elevated common impurity outside of the specified levels above does not preclude an application from being submitted as an ANDA."

The EU's parallel document is final, not draft, already in force: the EMA's "Guideline on the Development and Manufacture of Synthetic Peptides" (EMA/CHMP/CVMP/QWP/367182/2025), adopted December 2025, in effect 1 June 2026 (source 11), covered in full in our EMA guideline article. It routes thresholds through the European Pharmacopoeia: "...peptide-related impurities should be reported above 0.1%, identified above 0.5% and qualified above 1.0%." Impurities between 0.1 and 0.5 percent are fully evaluated against the reference product for comparability, at a 0.1 percent quantification limit. Two USP general chapters exist as reference points: General Chapter 1503, Quality Attributes of Synthetic Peptide Drug Substances (2021), and General Chapter 1504, Quality Attributes of Starting Materials for the Chemical Synthesis of Therapeutic Peptides (2023), which is meant to be used together with the 1503 chapter; both sit behind the USP-NF subscription past their free preview (source 12) (source 13).

The three documents, side by side:

Why the thresholds exist: immunogenicity, and four papers with interests

Thresholds exist because an impurity can trigger an immune response the parent peptide does not. FDA's withdrawn 2021 guidance divides impurities into three kinds: peptide-related, host-cell-related (found only in rDNA-origin products) and other, such as residual solvents and metals. For each new impurity, an applicant's data "should demonstrate... that the impurity does not contain sequences that have an increased affinity for major histocompatibility complex (MHC), known as T-cell epitopes." The same data should show that the proposed generic "...does not contain impurities or contaminants that produce a greater or distinct stimulation of innate immune activity as compared to the RLD." (source 1)

Four peer-reviewed papers, all indexed on PubMed, have actually tested pieces of this question, and each carries a declared or evident interest worth naming beside its finding. A study of synthetic generic versus recombinant brand glucagon (industry-authored; Han Q et al., PLoS One 2022, PMID 36409759 (source 14)) found "...the innate immunogenicity risk in the synthetic (generic) glucagon was at negligible level and comparable to the recombinant (brand-name) glucagon product." Its conflict-of-interest note reads: "The authors are employees of Amphastar Pharmaceuticals, Inc. at the time of the study and manuscript preparation." Amphastar markets a generic glucagon. A synthetic-versus-recombinant liraglutide study (industry-authored; Tang Y et al., Biochem Biophys Res Commun 2025, PMID 40398094 (source 15)) reported that "...despite differences in manufacturing processes between synthetic Liraglutide (generic) and recombinant Liraglutide (branded), there was no statistically significant difference in their immunogenicities." Three of its four authors are at Hybio Pharmaceutical Co., a synthetic-peptide manufacturer, the fourth at Tsinghua University, and the paper declares no competing interest. An FDA-co-authored, tool-vendor-led study of generic teriparatide impurities (Mattei AE et al., Front Immunol 2025, PMID 41445733 (source 16)), using in-silico, in-vitro and human T-cell assays against the reference drug Forteo, found that "The orthogonal approaches identified multiple impurities as more immunogenic than TPT." It also reported "...a potentially tolerogenic sequence in TPT, which correlated with lower-than-expected de novo immune responses to TPT in vitro." Five of its authors are at EpiVax Inc, owner of the three in-silico tools used, with the senior author its majority shareholder, alongside co-authors at FDA and CDER offices. An originator-authored study across five liraglutide suppliers (Staby A et al., Pharm Res 2020, PMID 32514880 (source 17)), all authors at Novo Nordisk A/S, the originator, one of them also at LEO Pharma, found that "Synthetic and recombinant liraglutide produced by five suppliers had distinct impurity profiles compared with the originator." Its conclusion: "Follow-on versions of liraglutide and semaglutide, and possibly other polypeptides, should be clinically evaluated for efficacy and safety."

The pattern: two manufacturer-authored studies found no meaningful innate-immune difference for their own generics, an originator-authored study found distinct profiles and called for clinical evaluation, and an FDA-co-authored, tool-vendor-led study found some teriparatide impurities more immunogenic. The reading these four support: the question is live and the parties have interests.

Who has made it through: the US list as of 29 August 2026

The five peptide drug products named in the original 2021 guidance, plus semaglutide and tirzepatide added by the July 2026 draft PSGs, are the ones to check. Four peptides with five first-generic approval entries stand on the US list. As of 29 August 2026, checked against the openFDA Drugs@FDA query and the nine FDA first-generic lists:

Amphastar's generic label states, verbatim: "Glucagon is produced by solid state peptide synthesis and is highly purified." (prescribing information) (source 23) The reference product's own label reads: "Glucagon is synthesized in a laboratory strain of Escherichia coli bacteria that has been genetically altered by the addition of the gene for..." (source 24). FDA's approval letter calls it "...bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Glucagon for Injection, 1 mg/vial of Eli Lilly and Company." (regulator release) (source 25) For teriparatide, FDA's Office of Pharmaceutical Quality recorded, verbatim: "1st Generic ANDA: A208569, Teva Pharmaceuticals USA Inc, approved on 11/16/2023, synthetic API and Q1/Q2 to RLD / A211097, Apotex Inc, approved on 11/16/2023, synthetic API and Q1/Q2 to RLD" (regulator release) (source 26) (source 27).

FDA's news release states the approval was "...the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter... indicated to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes..." (regulator release) (source 28). Teva's own release for the weight-management indication calls its product "...the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the U.S. market." (company release) (source 29).

Semaglutide has gone further than a filing and less far than an approval. Apotex Corp. announced, verbatim, that it "...has received the first U.S. Food and Drug Administration (FDA) Tentative Approval for its Abbreviated New Drug Application (ANDA) for Semaglutide Injection..." (company release) (source 30). Drugs@FDA records the action as "04/07/2026 | ORIG-1 | Tentative Approval" for ANDA 220314 (source 31): not an approval, and not on the US market. On 29 August 2026, openFDA listed six semaglutide applications: five Novo Nordisk NDAs with status "AP" and this one ANDA with status "TA" (source 32).

Ozempic (NDA 209637) and Wegovy (NDA 215256) share drug-substance patent 8,129,343, expiring 12/05/2031; Ozempic separately carries exclusivity I-961 to 01/28/2028 for a new kidney-disease indication, Wegovy two indication-specific exclusivities to 03/08/2027 and 08/15/2028 (source 33) (source 34) (source 35). As of 29 August 2026, no ANDA of any status for tirzepatide was located in the openFDA Drugs@FDA query or the nine FDA first-generic lists; Mounjaro (NDA 215866) and Zepbound (NDA 217806) share drug-substance patent 9,474,780, expiring 05/13/2036, and Zepbound's listed exclusivities expire 11/08/2026, 05/13/2027, 10/18/2027 and 12/20/2027 (source 36) (source 37). As of 29 August 2026, no ANDA for nesiritide or teduglutide was located in the openFDA Drugs@FDA query or the nine FDA first-generic lists either (source 32).

Outside the US: four regulators, four nouns for the same molecule

Health Canada authorized a first generic semaglutide on 28 April 2026: "Today, Health Canada authorized a generic semaglutide injection. This is the first generic semaglutide authorized by Health Canada, and the first to be approved in the G7." The filer: "The semaglutide injection submission filed by Dr. Reddy's Laboratories is a generic version of the brand name drug Ozempic." Health Canada's own regulatory language: "The generic versions of semaglutide are complex synthetic products that are pharmaceutically equivalent to the brand name biologic drug." (regulator release) (source 38) A second authorization followed 1 May 2026 (Apotex, with Orbicular Pharmaceutical Technologies, also an Ozempic generic) (source 39) (source 40), and a third on 29 June 2026 covered a Wegovy generic for weight loss, Sevmia, also Apotex, the third generic semaglutide product Health Canada authorized (source 41).

India moved on its own patent-expiry timeline: Dr. Reddy's Laboratories announced on 21 March 2026: "Dr. Reddy's has been the first Indian company to receive Drugs Controller General of India (DCGI) approval for generic semaglutide. This launch underscores the company's Day-1 entry into the segment upon patent expiry..." (company release) (source 42). The product, Obeda, 2 mg and 4 mg pens for type 2 diabetes, comes with the company's own claim: "In a head-to-head Phase-III clinical study enrolling 312 participants, Dr. Reddy's Obeda(R) has shown non-inferior efficacy and similar safety to the innovator drug..." at 4,200 Indian rupees per month; a company claim, not a regulator's published assessment.

Brazil's regulator has been the most explicit about rejecting "generic" for this category: Anvisa registered "Ozivy" (EMS/SA) on 26 May 2026, verbatim: "Ozivy não é um medicamento genérico, já que não há genérico de produtos biológicos conforme regulação brasileira. O produto é classificado como medicamento novo, sendo um análogo sintético de produto biológico." (regulator release) (source 43). Two more synthetic-semaglutide products referencing Ozivy followed on 17 August 2026, an EMS generic and Germed's "similar" Semaclique (source 44), then a second Germed generic reported by Agencia Brasil on 25 August 2026 (source 45).

For China, the record documents acceptance for review only, and nothing about later status: Hangzhou Jiuyuan Genetic Biopharmaceutical announced on 25 February 2026 that its product, Jikeqin, "...a biosimilar of the long-acting glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide...", had its "MARKETING APPLICATION... APPROVED BY NMPA" in the announcement's headline, while the body states the application "...has been accepted by the National Medical Products Administration..." (company release) (source 46). The status here, per that conflict, is accepted for review, not approved, as of 25 February 2026.

For the EU: we located no EU marketing authorisation for a generic or biosimilar semaglutide as of 29 August 2026; the EMA site could not be searched from our side, so read that as no finding, not as a finding of absence.

Four regulators, four nouns for the same molecule: Health Canada's "...complex synthetic products that are pharmaceutically equivalent to the brand name biologic drug." Anvisa's "medicamento novo", not genérico; China's biosimilar; and the US, which regulates a peptide of 40 or fewer amino acids as a drug and reviews the synthetic copy through an ANDA.

What 148,085 posts argue about, and the word that returns zero hits

Our corpus: 148,085 posts across eight peptide- and GLP-1-focused subreddits, 1 August 2025 to 5 August 2026, keyword-matched in title or body (source 47). Set the regulatory vocabulary above against it and the gap is stark: "legit" appears in 1,996 posts, "trust" in 1,508, "scam" in 1,383, "purity" or "purities" in 492, "COA", "CoA" or "certificate of analysis" in 435, "Janoshik" (a laboratory name, used here only as a search term) in 337, "generic(s)" in 242, and "FDA approved" or "FDA-approved" in 208, 64 of those "not FDA approved". "Immunogenic" appears in two posts; "ANDA", "505(j)", "reference listed drug", "bioequivalence", "product-specific guidance" and "Orange Book" each appear in zero posts.

133 posts name an actual purity percentage; the values named most often are "99" (69 mentions), "98" (10), "99.5" (9), "99.9" (6) and "95" (4). One thread asks what a percentage alone cannot answer: "Do you guys worry about TFA?", with a body fragment, lab name removed, "I can't tell if when I read a purity score... TFA contents count as an impurity or not". "How do I know COA's are even real?" (score 20, 21 comments) is a recurring question, the same one our guide to spotting a fake peptide CoA addresses directly; ten posts allege a fake or altered CoA, and 42 describe sending a sample in themselves.

"Generic" rose across the corpus year, in step with the events above: 78 of 67,633 posts from August 2025 to January 2026 (11.5 per 10,000), 164 of 80,452 posts from February to 5 August 2026 (20.4 per 10,000), the only normalized rates used here. This rise coincides in time with the non-US approvals above; this article says coincides, not caused. One widely read post shows the community-fact gap directly: "Generic ozempic is going to be $60/2mg. The grey market is never going away." (score 109, 70 comments) states in its body, "They benefit from generics already because Eli Lily screwed up the patent renewal." Ozempic's sponsor of record is Novo Nordisk, per Drugs@FDA, not Eli Lilly. FDA otherwise shows up in the corpus mostly around compounding enforcement, not generics. Against 39 "pharma grade" posts (95 combined with "research/lab grade" and "GMP"/"cGMP") and 435 CoA-mentioning posts, the document, not a grade word, is this community's working substitute for a standard.

One purity figure circulates with a specific paper behind it, and it needs its full context whenever used. The thread "Paper tested grey market semaglutide" (score 185) points to a study of three delivered semaglutide injection vials bought online without a prescription (J Med Internet Res 2024, PMID 39509151 (source 48)). Verbatim: "...the measured semaglutide purity was significantly low, ranging between 7.7% and 14.37% and deviating from the 99% claimed on product labels by manufacturers." And: "...endotoxin was detected in all samples with levels ranging between 2.1645 EU/mg and 8.9511 EU/mg." Three precisions belong with it. Only three vials were delivered and tested: "Three injection vial purchases were delivered; none of the 3 Ozempic prefilled injection pens were received due to nondelivery e-commerce scams." Measured content "...substantially exceeded labeled amounts by 28.56%-38.69%...", overdosed relative to label, not underdosed. And "...no peptide-like impurities were identified." The low purity figure is therefore not peptide by-products. One small study of three vials, not a description of any broader market.

Corpus limits, once: posts only, not comment text; two of eight subreddits hold 56.4 percent of posts (83,491 of 148,085); nothing about EU law; self-reports, not measurements.

What a research CoA shows, and what this standard is built from

A third-party research certificate of analysis in this space reports a purity percentage, which is a peak-area ratio from one chromatographic run (see our guide to reading an HPLC chromatogram); an identity result, given by mass, by retention time or by FTIR depending on the laboratory, and on some certificates without the method being named at all, a distinction covered in what HPLC and mass spectrometry actually prove; and, on some reports, an endotoxin result, either pass/fail or a numeric EU/mg value.

What the ANDA and EMA documents above are built from, and what a research CoA of this kind typically does not contain: identification of each named impurity against the report, identify and qualify thresholds above; a level-by-level comparison against a reference product; higher-order-structure testing (CD, FTIR, NMR, DSC); a comparative biological-activity assay; an immunogenicity assessment of any impurity; residual-solvent and elemental-impurity panels; or a comparability study.

A CoA answers one question: what is in this vial, and how much of the main peak is the named peptide. The standard this article describes answers a different one: is this the same active ingredient as a reference product, with an impurity profile that has been identified, compared against that reference product and justified. A purity percentage is not a statement about the second question, in either direction. Our own CoA page and our articles on how to read a certificate of analysis, what a CoA does not test and verifying a Janoshik CoA describe what our own reports contain; this article, like those, makes no claim that our reports meet or miss this standard. The corpus mirrors the same gap: "purity" appears in 492 posts, "impurities" in 29; the TFA question above is the precise example of what a specification answers and a percentage alone does not.

What to watch

The comment period on the 17 draft PSGs runs to 28 September 2026 (91 FR 47834). The FDA statement says: "As noted in the Center for Drug Evaluation and Research 2026 Guidance Agenda, FDA plans to revise the guidance this year." The Federal Register notice says "...FDA plans to revise and reissue the guidance this year." No date narrower than that is given. Health Canada was, as of 29 June 2026, still reviewing six further generic semaglutide submissions. In the US, semaglutide sits at one tentative approval (ANDA 220314), with Ozempic's and Wegovy's shared drug-substance patent running to 12/05/2031 and exclusivities running into 2028; as of 29 August 2026, no ANDA of any status for tirzepatide was located in the openFDA Drugs@FDA query or the nine FDA first-generic lists, and Mounjaro's drug-substance patent runs to 05/13/2036. For the EU: we located no EU marketing authorisation for a generic or biosimilar semaglutide as of 29 August 2026; the EMA site could not be searched from our side, so read that as no finding, not as a finding of absence. A separate FDA process worth tracking alongside this one: our coverage of the PCAC vote outcome.

Frequently asked questions

Sources

1. FDA. ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin. Guidance for Industry, May 2021 (withdrawn 28 July 2026). Archived copy: https://web.archive.org/web/20251214073809/https://www.fda.gov/media/107622/download
2. Federal Register. Abbreviated New Drug Applications for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of Recombinant Deoxyribonucleic Acid; Guidance for Industry; Availability. 86 FR 27446, Docket FDA-2017-D-5767, May 20, 2021. https://www.federalregister.gov/documents/2021/05/20/2021-10603/abbreviated-new-drug-applications-for-certain-highly-purified-synthetic-peptide-drug-products-that
3. FDA. FDA Publishes Revised Draft Product-Specific Guidances for Certain Generic Peptide Products. Drug Alerts and Statements, July 28, 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-publishes-revised-draft-product-specific-guidances-certain-generic-peptide-products
4. Federal Register. Product-Specific Guidances; Revised Draft Guidances for Industry; Availability. 91 FR 47834, Docket FDA-2007-D-0369, July 29, 2026; comments due September 28, 2026. https://www.federalregister.gov/documents/2026/07/29/2026-15285/product-specific-guidances-revised-draft-guidances-for-industry-availability
5. FDA. Draft Guidance on Semaglutide (Reference Listed Drug NDA 215256), July 2026. https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215256.pdf
6. FDA. Draft Guidance on Semaglutide (Reference Listed Drug NDA 209637), July 2026. https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209637.pdf
7. FDA. Draft Guidance on Teriparatide (Reference Listed Drugs NDA 021318, NDA 218771), July 2026. https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021318.pdf
8. FDA. Draft Guidance on Glucagon (Reference Listed Drug NDA 020928), July 2026. https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020928.pdf
9. FDA. Draft Guidance on Tirzepatide (Reference Listed Drugs NDA 215866 and NDA 217806), July 2026. https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215866.pdf and https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_217806.pdf
10. FDA. Draft Guidance on Liraglutide (Reference Listed Drug NDA 022341), July 2026. https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022341.pdf
11. European Medicines Agency. Guideline on the Development and Manufacture of Synthetic Peptides. EMA/CHMP/CVMP/QWP/367182/2025, 4 December 2025, in effect 1 June 2026. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-development-manufacture-synthetic-peptides_en.pdf
12. United States Pharmacopeia. General Chapter 1503, Quality Attributes of Synthetic Peptide Drug Substances. USP-NF, 2021. https://doi.org/10.31003/USPNF_M12935_02_01
13. United States Pharmacopeia. General Chapter 1504, Quality Attributes of Starting Materials for the Chemical Synthesis of Therapeutic Peptides. USP-NF, 2023. https://doi.org/10.31003/USPNF_M16255_02_01
14. Han Q, Bao Z, Luo MZ, Zhang JY. Assessment of innate immune response modulating impurities in glucagon for injection. PLoS One. 2022;17(11):e0277922. PMID 36409759. https://pubmed.ncbi.nlm.nih.gov/36409759/
15. Tang Y, Tang C, Lu X, Xing X. Assessment of innate immune response modulating impurities (IIRMI) in synthetic peptide drugs (liraglutide). Biochem Biophys Res Commun. 2025;771:151967. PMID 40398094. https://pubmed.ncbi.nlm.nih.gov/40398094/
16. Mattei AE, Roberts BJ, Lelias S, Miah S, Howard KE, Weaver JL, Verthelyi D, Pang ES, Edwards K, De Groot AS. Immunogenicity risk assessment of peptide-related impurities identified in generic teriparatide products. Front Immunol. 2025;16:1730346. PMID 41445733. https://pubmed.ncbi.nlm.nih.gov/41445733/
17. Staby A, Steensgaard DB, Haselmann KF, Marino JS, Bartholdy C, Videbaek N, Schelde O, Bosch-Traberg H, Spang LT, Asgreen DJ. Influence of Production Process and Scale on Quality of Polypeptide Drugs: a Case Study on GLP-1 Analogs. Pharm Res. 2020;37(7):120. PMID 32514880. https://pubmed.ncbi.nlm.nih.gov/32514880/
18. FDA. 2020 First Generic Drug Approvals. https://www.fda.gov/drugs/first-generic-drug-approvals/2020-first-generic-drug-approvals
19. FDA. 2023 First Generic Drug Approvals. https://www.fda.gov/drugs/drug-and-biologic-approval-and-ind-activity-reports/2023-first-generic-drug-approvals
20. FDA. 2024 First Generic Drug Approvals. https://www.fda.gov/drugs/drug-and-biologic-approval-and-ind-activity-reports/2024-first-generic-drug-approvals
21. Amneal Pharmaceuticals. Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist. Press release, November 21, 2024. https://investors.amneal.com/news/press-releases/press-release-details/2024/Amneal-Resubmits-DHE-Autoinjector-New-Drug-Application-and-Receives-U.S.-FDA-Approval-of-Exenatide-its-First-Generic-Injectable-GLP-1-Agonist/default.aspx
22. FDA. 2025 First Generic Drug Approvals. https://www.fda.gov/drugs/drug-and-biologic-approval-and-ind-activity-reports/2025-first-generic-drug-approvals
23. Amphastar Pharmaceuticals. Glucagon for Injection prescribing information (ANDA 208086), DailyMed SPL. https://www.accessdata.fda.gov/spl/data/7b1b15a9-4632-4749-b4ad-95dd0c5d3966/7b1b15a9-4632-4749-b4ad-95dd0c5d3966.xml
24. Eli Lilly and Company. Glucagon for Injection prescribing information, NDA 020928 supplement 60. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020928s060lbl.pdf
25. FDA. ANDA 208086 approval letter to Amphastar Pharmaceuticals, Inc., December 28, 2020. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/208086Orig1s000ltr.pdf
26. Jiao T. Teriparatide Injection First Generic Approval: Quality-Related Review Considerations. FDA CDER Office of Pharmaceutical Quality, Advancing Generic Drug Development 2024, September 25, 2024. https://www.fda.gov/media/184411/download
27. FDA. ANDA 208569 approval letter to Teva Pharmaceuticals USA, Inc., November 16, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/208569Orig1s000ltr.pdf
28. FDA. FDA Approves First Generic of Once-Daily GLP-1 Injection to Lower Blood Sugar in Patients with Type 2 Diabetes. News release, December 23, 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-first-generic-once-daily-glp-1-injection-lower-blood-sugar-patients-type-2-diabetes
29. Teva Pharmaceutical Industries. Teva Announces FDA Approval and Launch of Generic Saxenda (liraglutide injection). Press release, August 28, 2025. https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2025/Teva-Announces-FDA-Approval-and-Launch-of-Generic-Saxenda-liraglutide-injection--First-Generic-GLP-1-Indicated-for-Weight-Loss/default.aspx
30. Apotex Corp. Apotex Receives First U.S. FDA Tentative Approval for a Generic Version of Ozempic (Semaglutide Injection) in Partnership with Orbicular. Press release, April 10, 2026. https://www.apotex.com/global/news/news-release/2026/04/10/apotex-receives-first-us-fda-tentative-approval-for-a-generic-version-of-ozempic-semaglutide-injection-in-partnership-with-orbicular
31. FDA. Drugs@FDA, ANDA 220314 (semaglutide, Apotex Inc), tentative approval April 7, 2026. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220314
32. FDA. openFDA Drugs@FDA API, queries for nesiritide, teduglutide, semaglutide and tirzepatide applications, August 29, 2026. https://api.fda.gov/drug/drugsfda.json
33. FDA. Orange Book: Patent and Exclusivity for NDA 209637 (Ozempic), retrieved August 29, 2026. https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=001&Appl_No=209637&Appl_type=N
34. FDA. Orange Book: Exclusivity codes legend and individual references. https://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm
35. FDA. Orange Book: Patent and Exclusivity for NDA 215256 (Wegovy), retrieved August 29, 2026. https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=001&Appl_No=215256&Appl_type=N
36. FDA. Orange Book: Patent and Exclusivity for NDA 215866 (Mounjaro), retrieved August 29, 2026. https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=001&Appl_No=215866&Appl_type=N
37. FDA. Orange Book: Patent and Exclusivity for NDA 217806 (Zepbound), retrieved August 29, 2026. https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=001&Appl_No=217806&Appl_type=N
38. Health Canada. Canada becomes the first G7 country to approve a generic version of semaglutide. News release, April 28, 2026 (distributed via Canada Newswire). https://www.newswire.ca/news-releases/canada-becomes-the-first-g7-country-to-approve-a-generic-version-of-semaglutide-891114534.html
39. Apotex. Apotex becomes the first Canadian-based global pharmaceutical company to receive Health Canada approval for a generic equivalent of Ozempic. Press release, May 1, 2026. https://www.apotex.com/global/news/news-release/2026/05/01/apotex-becomes-the-first-canadian-based-global-pharmaceutical-company-to-receive-health-canada-approval-for-a-generic-equivalent-of-ozempic
40. Health Canada. Canada approves second generic semaglutide, the first G7 country to do so. News release, May 1, 2026. https://www.newswire.ca/news-releases/canada-approves-second-generic-semaglutide-the-first-g7-country-to-do-so-843116709.html
41. Health Canada. Canada approves first generic semaglutide for weight loss. News release, June 29, 2026. https://www.newswire.ca/news-releases/canada-approves-first-generic-semaglutide-for-weight-loss-849475481.html
42. Dr. Reddy's Laboratories. Dr. Reddy's Laboratories announces launch of India's first DCGI-approved Semaglutide injection 'Obeda' for Type 2 Diabetes. Press release, March 21, 2026, filed as Exhibit 99.1 to Form 6-K. https://www.sec.gov/Archives/edgar/data/1135951/000157587226000152/rdy0863_ex99-1.htm
43. Anvisa. Anvisa aprova primeira caneta de semaglutida sintetica analoga ao Ozempic para diabetes. May 26, 2026. https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026/anvisa-aprova-primeira-caneta-de-semaglutida-sintetica-analoga-ao-ozempic-para-diabetes
44. Anvisa. Anvisa aprova duas novas canetas para tratamento de diabetes. August 17, 2026. https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/anvisa-aprova-duas-novas-canetas-para-tratamento-de-diabetes
45. Agencia Brasil. Anvisa aprova segundo genérico de semaglutida em caneta injetavel. August 25, 2026. https://agenciabrasil.ebc.com.br/saude/noticia/2026-08/anvisa-aprova-segundo-generico-de-semaglutida-em-caneta-injetavel
46. Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. Voluntary announcement: marketing application for Jikeqin, February 25, 2026. HKEX. https://www.hkexnews.hk/listedco/listconews/sehk/2026/0225/2026022500908.pdf
47. Internal analysis of a public Reddit archive: 148,085 posts from eight peptide and GLP-1 subreddits, 1 August 2025 to 5 August 2026, keyword counts on title plus body, retrieved August 2026.
48. Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study. J Med Internet Res. 2024 Nov 7. PMID 39509151. https://pubmed.ncbi.nlm.nih.gov/39509151/

Research use only. Semaglutide, tirzepatide and retatrutide are referenced here for their published regulatory and research record. Products sold on this site are supplied for laboratory research, not for human or animal administration, and not as medicines. Nothing in this article is sourcing, testing, dosing or reconstitution guidance, and nothing here claims that any product, ours or any other, meets, approaches or fails the ANDA or EMA standard described.